Lowest Price Guaranteed From USD 4,799
Published
August 2023
Pages
255
View Count
6081
Example Insights
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
Report Description
The global plasmid DNA manufacturing market is anticipated to grow at compounded annual growth rate (CAGR) of ~15% during the forecast period. The plasmid DNA manufacturing market is a dynamic and rapidly growing sector that plays a pivotal role in biotechnology and genetic research. Plasmid DNA is a circular, double-stranded DNA molecule that replicates independently of chromosomal DNA. With its ability to be genetically engineered, plasmid DNA serves as a crucial component in the development of advanced therapy medicinal products (ATMPs), such as cell and gene therapy, and nucleic acid vaccines. Having said that, it is important to highlight that the current demand for plasmid DNA is experiencing an exponential growth due to the expanding landscape of cell and gene therapies. This surge in demand got further amplified in the global COVID-19 pandemic, as plasmid-based delivery became an indispensable approach in the development of RNA/DNA vaccines and therapeutics. During this time, several big pharma players, including Moderna and Pfizer-BioNTech utilized plasmid-based platforms for their mRNA vaccines, which significantly contributed towards increased demand for plasmid DNA.
However, the process of plasmid production is fraught with various challenges, including low yield, plasmid instability, and regulatory concerns, which necessitate specialized facilities and adherence to good manufacturing practices (GMP). As a result, an increasing number of researchers and drug developers are relying on contract service providers with specialized expertise and advanced technologies for their GMP plasmid manufacturing requirements. These service providers offer comprehensive services, including process development and optimization, plasmid construction, plasmid design, and plasmid engineering. In addition, there are specialty service providers that help to streamline the pDNA manufacturing process, optimize resource utilization, and ensure the delivery of high quality of plasmid DNA to fulfil the rigorous requirements of regulatory authorities and research standards. With growing demand for ATMPs and the increasing trend of outsourcing pDNA manufacturing operations, the pDNA manufacturing market is expected to witness substantial growth during the forecast period.
The “Plasmid DNA Manufacturing Market: Distribution by Scale of Operation (Commercial, Clinical and Preclinical), Application Area (Cell Therapy Manufacturing, Gene Therapy Manufacturing, DNA / RNA Vaccine Development, Viral Vector Manufacturing, and Other Application Areas), Therapeutic Area (Metabolic Disorders, Neurological Disorders, Oncological Disorders, Rare Disorders, and Other Disorders), and Geography (North America, Europe, Asia, Latin America, Middle East and North Africa, and Rest of the World): Industry Trends and Global Forecasts, 2023-2035” report features an extensive study of the current market landscape, market size and future opportunities within the plasmid DNA manufacturing market during the forecast period. The market report highlights the efforts of various stakeholders engaged in this rapidly emerging segment of the pharmaceutical industry. Key takeaways of the plasmid DNA manufacturing market are briefly discussed below.
The development and manufacturing of plasmid DNA requires significant investment in terms of time, expertise and resources. While a few large pharmaceutical companies have established in-house manufacturing facilities, the need for substantial capital investment and complex infrastructure to produce plasmid DNA has led many other drug developers to outsource pDNA manufacturing operations to specialized service providers. Consequently, there has been an increased emphasis on collaboration, aimed at outsourcing pDNA manufacturing operations to experienced partners. Outsourcing offers a viable solution to overcome challenges associated with plasmid stability, ensuring the integrity and functionality of the desired DNA constructs. Further, there are several challenges in scaling up plasmid DNA production particularly in process development, maintaining construct consistency, and ensuring reproducibility. These technical and operational obstacles have prompted pharmaceutical industry to increasingly rely on plasmid manufacturer with capability to provide contract services related to plasmid manufacturing. Additionally, the COVID-19 pandemic has fueled a surge in outsourcing activities, because of the rising demand for nucleic acid-based COVID-19 vaccines. In response to this urgent global need, numerous vaccine developers have established strategic collaborations with contract service providers to effectively meet the demand.
The current market landscape features the presence of over 70 companies offering a range of plasmid DNA services, including plasmid design, plasmid engineering and plasmid construction, process development and optimization, and plasmid manufacturing. Overall, the market seems to be well-fragmented, featuring the presence of very small, small, mid-sized, large, and very large companies having the required expertise to offer pDNA manufacturing services across different scales of operations, such as preclinical, clinical, and commercial. It is worth mentioning that around 80% of the plasmid manufacturer offer GMP grade plasmid DNA for commercial scale applications; notable examples (which have also been captured in this market report) include AGC Biologics, Aldevron, Biomay, Catalent Pharma Solutions, Charles River, Cytovance Biologics, Forge Biologics, GenScript ProBio, Thermo Fisher Scientific, and VGXI.
The plasmid DNA industry is on the verge of groundbreaking revolution, driven by the emergence of Doggybone DNA™ (dbDNA) technology developed by Touchlight. This pioneering linear plasmid technology, produced abiotically through rolling circle amplification, represents a seismic shift in this field. DbDNA™ offers unparalleled advantages, including enhanced stability, simplified purification, and cost-effective scalability, challenging conventional plasmid production methods. With its remarkable versatility in genetic engineering, gene therapy, and mRNA production, dbDNA™ stands as a highly promising solution. It is interesting to note that in February 2023, Touchlight received FDA clearance for the Investigational New Drug (IND) application utilizing doggybone DNA (dbDNA™) as an in vitro transcription template for mRNA production in the manufacturing of a cell therapy product. Adoption of such novel plasmid DNA technologies will support the efforts of the industry to meet the growing demand for this starting material for cell therapy and mRNA therapy. Novel technologies will propel the plasmid DNA manufacturing market growth during the forecast period.
Examples of key plasmid manufacturer (which have also been profiled in this report) offering pDNA manufacturing services include (in alphabetical order) AGC Biologics, Aldevron, Biomay, Charles River, Cytovance Biologics, Forge Biologics, GenScript ProBio, Thermo Fisher Scientific, and VGXI. It is interesting to note that in January 2023, Charles River expanded its portfolio by launching eXpDNA™ plasmid manufacturing platform, in order to offer efficient and accelerated GMP plasmid manufacturing and supply services to ATMP developers. Such portfolio additions are expected to drive plasmid DNA manufacturing market growth during the forecast period.
The players in this market are continuously expanding their facilities in order to accommodate the growing demand for plasmid DNA. They are vigorously advancing their capabilities to serve as a fully integrated one-stop-shop by offering a range of plasmid services, including process development and optimization, plasmid design, plasmid engineering and plasmid construct, and GMP plasmid manufacturing. In January 2023, Catalent Pharma Solutions, a US-based CDMO, established a new commercial scale plasmid development and manufacturing facility to expand its end-to-end capabilities for the production of GMP grade plasmid DNA. Increase in the demand for plasmid DNA to support the production of cell and gene therapies is one of the reasons for the facility / capability expansion by the contract organizations.
Stakeholders in the plasmid manufacturing industry have forged several partnerships in order to enhance their service portfolios and augment the reach of their proprietary plasmid DNA technology. It is worth highlighting that over 55% of these partnerships have been inked since 2021. Notably, majority of such deals are focused on manufacturing and supply of plasmid products, followed by product development and technology utilization agreements. In May 2023, Aldevron signed an agreement with Evanoa Bioscience to improve its fermentation process by using latter’s novel strains of Escherichia Coli. In another similar deal inked between AcuraBio and Cytiva in February 2023, the former company adopted Cytiva’s single-use bacterial plasmid purification technology to expand its cGMP pDNA manufacturing service.
Driven by the increasing adoption of gene therapies and rising demand for nucleic acid vaccines, the plasmid DNA manufacturing market is anticipated to grow at an annualized rate (CAGR) of ~15% during the forecast period 2023-2035. It is worth highlighting that, in terms of application area, gene therapy manufacturing is expected to capture the majority market share in the plasmid DNA manufacturing market in 2023.
Several recent developments have taken place in the field of plasmid manufacturing. Some of these recent initiatives have been mentioned below. These developments, even if they took place post the release of our market report, substantiate the overall market trends that we have outlined in our analyses.
The study presents an in-depth analysis of the various firms / organizations that are engaged in this domain, across different segments as defined in the below table:
| Key Report Attributes | Details | |
|
Historical Trend |
2018-2022 |
|
|
Base Year |
2022 |
|
|
Forecast Period |
2023-2035 |
|
|
CAGR |
~15% |
|
|
Scale of Operation |
|
|
|
Application Area |
|
|
|
Therapeutic Area |
|
|
|
Geograpy |
|
|
|
Key Companies Profiled |
(Full list of more than 70 companies captured is available in the report) |
|
|
PowerPoint Presentation (Complimentary) |
Available |
|
|
Customization Scope |
15% Free Customization Option |
|
|
Excel Data Packs (Complimentary) |
|
|
The market report presents an in-depth analysis, highlighting the capabilities of various companies engaged in this industry, across different geographies. Amongst other elements, the market research report features:
The key objective of this market report is to provide a detailed market forecast analysis in order to estimate the existing market size and future opportunity for plasmid manufacturer over the next decade. Based on multiple parameters, likely adoption trends and through primary validations, we have provided an informed estimate on the market evolution during the forecast period 2023-2035. The report also features the likely distribution of the current and forecasted opportunity within the plasmid DNA manufacturing market across various segments, such as scale of operation (commercial, clinical, and preclinical), application area (cell therapy manufacturing, gene therapy manufacturing, DNA / RNA vaccine development, and viral vector manufacturing, and other application areas), therapeutic area (metabolic disorders, neurological disorders, oncological disorders, rare disorders, and other disorders), and geography (North America, Europe, Asia, Latin America, Middle East and North Africa and rest of the world). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.
The opinions and insights presented in the market report were influenced by discussions held with stakeholders in the industry. The report features detailed transcripts of interviews held with the following industry stakeholders:
All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this market report are in USD, unless otherwise specified.
Contents
1. PREFACE
1.1. Introduction
1.2. Project Objectives
1.3. Scope of the Report
1.4. Inclusions and Exclusions
1.5. Key Questions Answered
1.6. Chapter Outlines
2. RESEARCH METHODOLOGY
2.1. Chapter Overview
2.2. Research Assumptions
2.3. Project Methodology
2.4. Forecast Methodology
2.5. Robust Quality Control
2.6. Key Market Segmentations
2.7. Key Considerations
2.7.1. Demographics
2.7.2. Economic Factors
2.7.3. Government Regulations
2.7.4. Supply Chain
2.7.5. COVID Impact / Related Factors
2.7.6. Market Access
2.7.7. Healthcare Policies
2.7.8. Industry Consolidation
3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS
3.1. Chapter Overview
3.2. Market Dynamics
3.2.1. Time Period
3.2.1.1. Historical Trends
3.2.1.2. Current and Forecasted Estimates
3.2.2. Currency Coverage
3.2.2.1. Overview of Major Currencies Affecting the Market
3.2.2.2. Impact of Currency Fluctuations on the Industry
3.2.3. Foreign Exchange Impact
3.2.3.1. Evaluation of Foreign Exchange Rates and Their Impact on Market
3.2.3.2. Strategies for Mitigating Foreign Exchange Risk
3.2.4. Recession
3.2.4.1. Historical Analysis of Past Recessions and Lessons Learnt
3.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market
3.2.5. Inflation
3.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
3.2.5.2. Potential Impact of Inflation on the Market Evolution
4. EXECUTIVE SUMMARY
5. INTRODUCTION
5.1. Chapter Overview
5.2. Overview of Plasmids
5.2.1. Structure of a Plasmid DNA
5.3. Types of Plasmids (By Function)
5.3.1. Fertility Plasmids
5.3.2. Resistance Plasmids
5.3.3. Virulence Plasmids
5.3.4. Degradative Plasmids
5.3.5. Col Plasmids
5.4. Plasmid DNA Manufacturing
5.4.1. Steps Involved in Plasmid DNA Manufacturing
5.5. Applications of Plasmid DNA in Pharmaceutical Industry
5.5.1. Cell and Gene Therapy Manufacturing
5.5.2. Viral Vector Manufacturing
5.5.3. Vaccine Development
5.5.4. Other Research Applications
5.6. Challenges Associated with Plasmid DNA Manufacturing
5.7 Need for Outsourcing Plasmid DNA Manufacturing
5.8 Future Perspectives
6. OVERALL MARKET LANDSCAPE
6.1. Chapter Overview
6.2. Plasmid DNA Service Providers: Overall Market Landscape
6.3. Analysis by Year of Establishment
6. 4. Analysis by Company Size
6.5. Analysis by Location of Headquarters
6.6. Analysis by Type of Company
6.7. Analysis by Type of Venture
6.8. Analysis by Type of Service(s) Offered
6.8.1. Analysis by Location of Manufacturing Facility
6.9. Analysis by Key Offerings
6.10. Analysis by Grade of Plasmid DNA
6.11. Analysis by Scale of Operation
6.12. Analysis by Application Area(s)
7. KEY INSIGHTS
7.1. Chapter Overview
7.2. Plasmid DNA Service Providers: Key Insights
7.2.1 Analysis by Company Size and Location of Headquarters
7.2.2. Analysis by Company Size and Type of Venture
7.2.3. Analysis by Key Offerings and Location of Headquarters
7.2.4. Analysis by Scale of Operation and Company Size
7.2.5. Analysis by Grade of Plasmid DNA and Application Area(s)
7.2.6. Analysis by Scale of Operation, Application Area(s) and Location of Manufacturing Facility
8. PARTNERSHIPS AND COLLABORATIONS
8.1. Chapter Overview
8.2. Partnership Models
8.3. Plasmid DNA Services: Partnerships and Collaborations
8.3.1. Analysis by Year of Partnership
8.3.2. Analysis by Type of Partnership
8.3.3. Analysis by Year and Type of Partnership
8.3.4. Analysis by Type of Partner
8.3.5. Analysis by Type of Partnership and Type of Partner
8.3.6. Analysis by Grade of Plasmid DNA
8.3.7. Analysis by Scale of Operation
8.3.8 Analysis by Geography
8.3.8.1. Local and International Agreements
8.3.8.2. Intercontinental and Intracontinental Agreements
8.3.9. Most Active Players: Analysis by Number of Partnerships
9. ACQUISITIONS
9.1. Chapter Overview
9.2. Acquisitions Models
9.3. Plasmid DNA Services Providers: Acquisitions
9.3.1. Analysis by Year of Acquisition
9.3.2. Analysis by Type of Acquisition
9.3.3. Analysis by Geography
9.3.3.1. Local and International Acquisitions
9.3.3.2. Intercontinental and Intracontinental Acquisitions
9.3.4. Ownership Change Matrix
9.3.5. Analysis by Company Size
9.3.6. Analysis by Key Value Drivers
9.3.7. Valuation Analysis: Acquisition Deal Multiples
9.3.8. Most Active Players: Analysis by Number of Acquisitions
10. CAPACITY ANALYSIS
10.1. Chapter Overview
10.2. Key Assumptions and Methodology
10.3. Plasmid DNA Manufacturing: Global Installed Capacity
10.3.1. Analysis by Company Size
10.3.2. Analysis by Scale of Operation
10.3.3. Analysis by Location of Manufacturing Facility
10.4. Concluding Remarks
11. COMPANY COMPETITIVENSS ANALYSIS
11.1. Chapter Overview
11.2. Assumptions and Key Parameters
11.3. Methodology
11.4. Plasmid DNA Manufacturing Service Providers: Company Competitiveness Analysis
11.4.1. Benchmarking of Service Strength
11.3.2. Benchmarking of Partnership Activity
11.3.3. Very Small Companies Offering Plasmid DNA Manufacturing
11.3.4. Small Companies Offering Plasmid DNA Manufacturing
11.3.5. Mid-Sized Companies Offering Plasmid DNA Manufacturing
11.3.6. Large Companies Offering Plasmid DNA Manufacturing
11.3.7. Very Large Companies Offering Plasmid DNA Manufacturing
12. COMPANY PROFILES
12.1. Chapter Overview
12.2. AGC Biologics
12.2.1. Company Overview
12.2.2. Service Portfolio
12.2.3. Recent Developments and Future Outlook
12.3. Aldevron (Acquired by Danaher)
12.3.1. Company Overview
12.3.2. Service Portfolio
12.3.3. Financial Information
12.3.4. Recent Developments and Future Outlook
12.4. Biomay
12.4.1. Company Overview
12.4.2. Service Portfolio
12.4.3. Recent Developments and Future Outlook
12.5. Catalent Pharma Solutions
12.5.1. Company Overview
12.5.2. Service Portfolio
12.5.3. Financial Information
12.5.4. Recent Developments and Future Outlook
12.6. Charles River
12.6.1. Company Overview
12.6.2. Service Portfolio
12.6.3. Financial Information
12.6.4. Recent Developments and Future Outlook
12.7. Cytovance Biologics
12.7.1. Company Overview
12.7.2. Service Portfolio
12.7.3. Recent Developments and Future Outlook
12.8. Forge Biologics
12.8.1. Company Overview
12.8.2. Service Portfolio
12.8.3. Recent Developments and Future Outlook
12.9. GenScript ProBio (a Subsidiary of GenScript)
12.9.1. Company Overview
12.9.2. Service Portfolio
12.9.3. Financial Information
12.9.4. Recent Developments and Future Outlook
12.10. Patheon pharma services (Acquired by Thermo Fisher Scientific)
12.10.1. Company Overview
12.10.2. Service Portfolio
12.10.3. Financial Information
12.10.4. Recent Developments and Future Outlook
12.11. VGXI
12.11.1. Company Overview
12.11.2. Service Portfolio
12.11.3. Recent Developments and Future Outlook
12.12. 53Biologics
12.12.1. Company Overview
12.11.2. Service Portfolio
12.13. Boehringer Ingelheim
12.13.1. Company Overview
12.13.2. Service Portfolio
12.14. Centre for Breakthrough Medicine (CBM)
12.14.1. Company Overview
12.14.2. Service Portfolio
12.15. JAFRAL Biosolutions
12.15.1. Company Overview
12.15.2. Service Portfolio
12.16. PackGene
12.16.1. Company Overview
12.16.2. Service Portfolio
12.17. Acural Bio
12.17.1. Company Overview
12.17.2. Service Portfolio
12.18. Hanmi BioPlant
12.18.1. Company Overview
12.18.2. Service Portfolio
12.19. BioCina
12.19.1. Company Overview
12.19.2. Service Portfolio
12.20. NorthXBiologics
12.21.1. Company Overview
12.22.2. Service Portfolio
12.21. Xpress Biologics
12.21.1. Company Overview
12.21.2. Service Portfolio
12.22. Eurogentec
12.22.1. Company Overview
12.22.2. Service Portfolio
12.23. ESCO Aster
12.23.1. Company Overview
12.23.2. Service Portfolio
12.24. Southern RNA
12.24.1. Company Overview
12.24.2. Service Portfolio
12.25. Richter-Helm
12.25.1. Company Overview
12.25.2. Service Portfolio
12.26. Aurigene Pharmaceutical Services
12.26.1. Company Overview
12.26.2. Service Portfolio
12.27. Wuxi AppTech
12.27.1. Company Overview
12.27.2. Service Portfolio
13. DEMAND ANALYSIS
13.1. Chapter Overview
13.2. Key Assumptions and Methodology
13.3. Global Demand for Plasmid DNA, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
13.3.1. Analysis by Scale of Operation
13.3.1.1. Commercial Demand for Plasmid DNA, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
13.3.1.2. Clinical Demand for Plasmid DNA, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
13.3.1.3. Preclinical Demand for Plasmid DNA, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
13.3.2. Analysis by Application Area
13.3.2.1. Plasmid DNA Demand for Cell Therapy Manufacturing, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
13.3.2.2. Plasmid DNA Demand for Gene Therapy Manufacturing, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
13.3.2.3. Plasmid DNA Demand for DNA / RNA Vaccine Development, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
13.3.2.4. Plasmid DNA Demand for Viral Vector Manufacturing, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
13.3.2.5. Plasmid DNA Demand for Other Application Areas, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
13.3.3. Analysis by Geography
13.3.3.1. Demand for Plasmid DNA in North America, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
13.3.3.2. Demand for Plasmid DNA in Europe, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
13.3.3.3. Demand for Plasmid DNA in Asia, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
13.3.3.4. Demand for Plasmid DNA in Latin America, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
13.3.3.5. Demand for Plasmid DNA in Middle East and North Africa, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
13.3.3.6. Demand for Plasmid DNA in Rest of the World, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
14. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES
14.1. Chapter Overview
14.2. Market Drivers
14.3. Market Restraints
14.4. Market Opportunities
14.5. Market Challenges
14.6. Conclusion
15. GLOBAL PLASMID DNA MANUFACTURING MARKET
15.1. Chapter Overview
15.2. Assumptions and Methodology
15.3. Global Plasmid DNA Manufacturing Market, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
15.3.1. Scenario Analysis
15.4. Key Market Segmentations
15.5. Dynamic Dashboard
16. PLASMID DNA MANUFACTURING MARKET, BY SCALE OF OPERATION
16.1. Chapter Overview
16.2. Key Assumptions and Methodology
16.3. Commercial Products: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
16.4. Clinical Products: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
16.5. Preclinical Products: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
16.6. Data Triangulation
16.6.1. Insights from Primary Research
16.6.2. Insights from Secondary Research
16.6.3. Insights from In-house Repository
17. PLASMID DNA MANUFACTURING MARKET, BY APPLICATION AREA
17.1. Chapter Overview
17.2. Key Assumptions and Methodology
17.3. Cell Therapy Manufacturing: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
17.4. DNA / RNA Vaccine Development: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
17.5. Viral Vector Manufacturing: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
17.6. Other Application Areas: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
17.8. Data Triangulation
17.8.1. Insights based on Primary Research
17.8.2. Insights based on Secondary Research
17.8.3. Insights from In-house Repository
18. PLASMID DNA MANUFACTURING MARKET, BY THERAAPEUTIC AREA
18.1. Chapter Overview
18.2. Key Assumptions and Methodology
18.3. Metabolic Disorders: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
18.4. Neurological Disorders: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
18.5. Oncological Disorders: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
18.6. Rare Disorders: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
18.7. Other Disorders: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
18.8. Data Triangulation
18.8.1. Insights based on Primary Research
18.7.2. Insights based on Secondary Research
18.7.3. Insights from In-house Repository
19. PLASMID DNA MANUFACTURING MARKET, BY GEOGRAPHY
19.1. Chapter Overview
19.2. Key Assumptions and Methodology
19.3. North America: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
19.4. Europe: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
19.5. Asia: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
19.6. Latin America: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
19.7. Middle East and North Africa: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
19.8. Rest of the World: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
19.9. Data Triangulation
19.9.1. Insights based on Primary Research
19.9.2. Insights based on Secondary Research
19.9.3. Insights from In-house Repository
20 CONCLUSION
21. EXECUTIVE INSIGHTS
21.1. Chapter Overview
21.2. JAFRAL Biosolutions
21.2.1. Company Snapshot
21.2.2. Interview Transcript: Frenk Smrekar, Chief Executive Officer and Co-Founder
21.3. Aldevron (Acquired by Danaher)
21.3.1. Company Snapshot
21.3.2. Interview Transcript: Jeff Briganti, Senior Director of Global Strategic Marketing
21.4. 53Biologics
21.4.1. Company Snapshot
21.4.2. Interview Transcript: Francisco Manuel Reyes Sosa, Business Development Manager
21.5. Center for Breakthrough Medicines (CBM)
21.5.1. Company Snapshot
21.5.2. Interview Transcript: Blaine Rathmann, Client Engagement Manager
22. APPENDIX 1: TABULATED DATA
23. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
Figure 4.1 Executive Summary: Overall Market Landscape
Figure 4.2 Executive Summary: Partnerships and Collaborations
Figure 4.3 Executive Summary: Acquisitions
Figure 4.4 Executive Summary: Capacity Analysis
Figure 4.5 Executive Summary: Demand Analysis
Figure 4.6 Executive Summary: Market Forecast and Opportunity Analysis
Figure 5.1 Steps Involved in Plasmid DNA Manufacturing
Figure 5.2 Applications of Plasmid DNA in Pharmaceutical Industry
Figure 5.3 Challenges Associated with Plasmid DNA Manufacturing
Figure 6.1 Plasmid DNA Service Providers: Distribution by Year of Establishment
Figure 6.2 Plasmid DNA Service Providers: Distribution by Company Size
Figure 6.3 Plasmid DNA Service Providers: Distribution by Location of Headquarters(Region-wise)
Figure 6.4 Plasmid DNA Service Providers: Distribution by Location of Headquarters (Country-wise)
Figure 6.5 Plasmid DNA Service Providers: Distribution by Type of Company
Figure 6.6 Plasmid DNA Service Providers: Distribution by Type of Venture
Figure 6.7 Plasmid DNA Service Providers: Distribution by Type of Service(s) Offered
Figure 6.8 Plasmid DNA Manufacturers: Distribution by Location of Manufacturing Facility
Figure 6.9 Plasmid DNA Service Providers: Distribution by Key Offerings
Figure 6.10 Plasmid DNA Service Providers: Distribution by Grade of Plasmid DNA
Figure 6.11 Plasmid DNA Service Providers: Distribution by Scale of Operation
Figure 6.12 Plasmid DNA ServiceProviders: Distribution by Application Area(s)
Figure 7.1 Key Insights: Distribution by Company Size and Location of Headquarters
Figure 7.2 Key Insights: Distribution by Company Size and Type of Venture
Figure 7.3 Key Insights: Distribution by Key Offerings and Location of Headquarters
Figure 7.4 Key Insights: Distribution by Scale of Operation and Company Size
Figure 7.5 Key Insights: Distribution by Grade of Plasmid DNA and Application Area(s)
Figure 7.6 Key Insights: Distribution by Scale of Operation, Application Area(s) and Location of Manufacturing Facility
Figure 8.1 Partnerships and Collaborations: Cumulative Year-Wise Trend, 2015-2023
Figure 8.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 8.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership, 2015-2023
Figure 8.4 Partnerships and Collaborations: Distribution by Type of Partner
Figure 8.5 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
Figure 8.6 Partnerships and Collaborations: Distribution by Grade of Plasmid DNA
Figure 8.7 Partnerships and Collaborations: Distribution by Scale of Operation
Figure 8.8 Partnerships and Collaborations: Local and International Agreements
Figure 8.9 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Figure 8.10 Most Active Players: Distribution by Number of Partnerships
Figure 9.1 Acquisitions: Cumulative Year-Wise Trend, 2015-2023
Figure 9.2 Acquisitions: Distribution by Type of Acquisition
Figure 9.3 Acquisitions: Local and International Deals
Figure 9.4 Acquisitions: Intercontinental and Intracontinental Deals
Figure 9.5 Acquisitions: Ownership Change Matrix
Figure 9.6 Acquisitions: Distribution by Company Size
Figure 9.7 Acquisitions: Distribution by Key Value Drivers
Figure 9.8 Acquisitions: Valuation by Acquisition Deal Multiples
Figure 9.9 Most Active Players: Distribution by Number of Acquisitions
Figure 10.1 Minimum, Average and Maximum Installed Plasmid DNA Manufacturing Capacity (Sample Dataset) (in Liters): Distribution by Company Size
Figure 10.2 Global Installed Plasmid DNA Manufacturing Capacity (in Liters): Distribution by Company Size
Figure 10.3 Global Installed Plasmid DNA Manufacturing Capacity (in Liters): Distribution by Scale of Operation
Figure 10.4 Global Installed Plasmid DNAManufacturing Capacity (in Liters): Distribution by Location of Manufacturing Facility
Figure 11.1 Company Competitiveness Analysis: Benchmarking of Service Strength
Figure 11.2 Company Competitiveness Analysis: Benchmarking of Partnership Activity
Figure 11.3 Company Competitiveness Analysis: Very Small Companies Offering Plasmid DNA Manufacturing
Figure 11.4 Company Competitiveness Analysis: Small Companies Offering Plasmid DNA Manufacturing
Figure 11.5 Company Competitiveness Analysis: Mid-Sized Companies Offering Plasmid DNA Manufacturing
Figure 11.6 Company Competitiveness Analysis: Large Companies Offering Plasmid DNA Manufacturing
Figure 11.7 Company Competitiveness Analysis: Very Large Companies Offering Plasmid DNA Manufacturing
Figure 12.1 Danaher: Annual Revenues, 2017-2022 (USD Billion)
Figure 12.2 Catalent Pharma Solutions: Annual Revenues, 2017-2022 (USD Billion)
Figure 12.3 Charles River: Annual Revenues, 2017-2022 (USD Billion)
Figure 12.4 GenScript: Annual Revenues, 2017-2022 (USD Billion)
Figure 12.5 Thermo Fisher Scientific: Annual Revenues, 2017-2022 (USD Billion)
Figure 13.1 Global Demand for Plasmid DNA, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (In Kgs)
Figure 13.2 Demand for Plasmid DNA: Distribution by Scale of Operation, 2018, 2023 and 2035
Figure 13.3 Commercial Demand for Plasmid DNA, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (In Kgs)
Figure 13.4 Clinical Demand for Plasmid DNA, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (In Kgs)
Figure 13.5 Preclinical Demand for Plasmid DNA, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (In Kgs)
Figure 13.6 Demand for Plasmid DNA: Distribution by Application Area, 2018, 2023 and 2035
Figure 13.7 Plasmid DNA Demand for Cell Therapy Manufacturing, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (In Kgs)
Figure 13.8 Plasmid DNA Demand for Gene Therapy Manufacturing, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (In Kgs)
Figure 13.9 Plasmid DNA Demand for DNA / RNA Vaccine Development, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (In Kgs)
Figure 13.10 Plasmid DNA Demand for Viral Vector Manufacturing, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (In Kgs)
Figure 13.11 Plasmid DNA Demand for Other Application Areas, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
Figure 13.12 Demand for Plasmid DNA: Distribution by Geography, 2018, 2023 and 2035
Figure 13.13 Demand for Plasmid DNA in North America, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (In Kgs)
Figure 13.14 Demand for Plasmid DNA in Europe, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (In Kgs)
Figure 13.15 Demand for Plasmid DNA in Asia, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (In Kgs)
Figure 13.16 Demand for Plasmid DNA in Latin America, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (In Kgs)
Figure 13.17 Demand for Plasmid DNA inMiddle East and North Africa, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (In Kgs)
Figure 13.18 Demand for Plasmid DNA in Rest of the World, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (In Kgs)
Figure 15.1 Global Plasmid DNA Manufacturing Market, Historical Trends (2018-2022)
Figure 15.2 Global Plasmid DNA Manufacturing Market, Forecasted Estimates (2023-2035), Base Scenario (USD Million)
Figure 15.3 Global Plasmid DNA Manufacturing Market, Forecasted Estimates (2023-2035), Conservative Scenario (USD Billion)
Figure 15.4 Global Plasmid DNA Manufacturing Market, Forecasted Estimates (2023-2035), Optimistic Scenario (USD Billion)
Figure 16.1 Plasmid DNA Manufacturing Market: Distribution by Scale of Operation, 2018, 2023 and 2035
Figure 16.2 Plasmid DNA Manufacturing Market for Commercial Products, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Figure 16.3 Plasmid DNA Manufacturing Market for Clinical Products, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Figure 16.4 Plasmid DNA Manufacturing Market for Preclinical Products, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Figure 17.1 Plasmid DNA Manufacturing Market: Distribution by Application Area, 2018, 2023 and 2035
Figure 17.2 Plasmid DNA Manufacturing Market for Cell Therapy Manufacturing, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Figure 17.3 Plasmid DNA Manufacturing Market for Gene Therapy Manufacturing, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Figure 17.4 Plasmid DNA Manufacturing Market for DNA / RNA Vaccine Development, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Figure 17.5 Plasmid DNA Manufacturing Market for Viral Vector Manufacturing, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Figure 17.6 Plasmid DNA Manufacturing Market for Other Application Areas, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Figure 14.12 Plasmid DNA ManufacturingMarket: Distribution by Therapeutic Area, 2018, 2023 and 2035
Figure 18.1 Plasmid DNA Manufacturing Market for Metabolic Disorders, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Figure 18.2 Plasmid DNA Manufacturing Market for Neurological Disorders, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Figure 18.3 Plasmid DNA Manufacturing Market for Oncological Disorders, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Figure 18.4 Plasmid DNA Manufacturing Market for Rare Disorders, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Figure 18.5 Plasmid DNA Manufacturing Market for Other Disorders, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Figure 19.1 Plasmid DNA Manufacturing Market: Distribution by Geography, 2018, 2023 and 2035
Figure 19.2 Plasmid DNA Manufacturing Market in North America, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Figure 19.3 Plasmid DNA Manufacturing Market in Europe, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Figure 19.4 Plasmid DNA Manufacturing Market in Asia, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Figure 19.5 Plasmid DNA Manufacturing Market in Latin America, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Figure 19.6 Plasmid DNA Manufacturing Market in Middle East and North Africa, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Figure 19.7 Plasmid DNA Manufacturing Market in Rest of the World, Historical Trends (2018-2022) and Forecasted Estimates (2023-2035) (USD Billion)
Figure 20.1 Concluding Remarks: Overall Market Landscape
Figure 20.2 Concluding Remarks: Partnerships and Collaborations
Figure 20.3 Concluding Remarks: Acquisitions
Figure 20.4 Concluding Remarks: Company Competitiveness Analysis
Figure 20.5 Concluding Remarks: CapacityAnalysis
Figure 20.6 Concluding Remarks: DemandAnalysis
Figure 20.7 Concluding Remarks: Market Forecast and Opportunity Analysis (I/II)
Figure 20.8 Concluding Remarks: Market Forecast and Opportunity Analysis (II/II)
Figure 20.9 Concluding Remarks: Key Growth Drivers and Restraints
Table 6.1 List of Plasmid DNA Service Providers
Table 6.2 Plasmid DNA Service Providers: Information on Type of Service(s) Offered
Table 6.3 Plasmid DNA Manufacturing Service Providers: Information on Location of Manufacturing Facility
Table 6.4 Plasmid DNA Service Providers: Information on Key Offerings
Table 6.5 Plasmid DNA Service Providers: Information on Grade of Plasmid DNA
Table 6.6 Plasmid DNA Service Providers: Information on Scale of Operation
Table 6.7 Plasmid DNA Service Providers: Information on Application Area(s)
Table 8.1 Plasmid DNA Services: List of Partnerships and Collaborations, 2015-2023
Table 8.2 Partnerships and Collaborations: Information on Type of Agreement (Country-wise and Continent-wise), 2015-2023
Table 9.1 Plasmid DNA Service Providers: List of Acquisitions, 2015-2023
Table 10.1 Plasmid DNA Manufacturers: Information on Production Capacity
Table 12.1 AGC Biologics: Company Snapshot
Table 12.2 AGC Biologics: Service Portfolio
Table 12.3 AGC Biologics: Recent Developments and Future Outlook
Table 12.4 Aldevron (Acquired by Danaher): Company Snapshot
Table 12.5 Aldevron (Acquired by Danaher): Service Portfolio
Table 12.6 Aldevron (Acquired by Danaher): Recent Development and Future Outlook
Table 12.7 Biomay: Company Snapshot
Table 12.7 Biomay: Service Portfolio
Table 12.8 Biomay: Recent Developments and Future Outlook
Table 12.9 Catalent Pharma Solutions: Company Snapshot
Table 12.10 Catalent Pharma Solutions: Service Portfolio
Table 12.11 Catalent Pharma Solutions: Recent Developments and Future Outlook
Table 12.12 Charles River: Company Snapshot
Table 12.13 Charles River: ServicePortfolio
Table 12.14 Charles River: Recent Developments and Future Outlook
Table 12.15 Cytovance Biologics: Company Snapshot
Table 12.16 Cytovance Biologics: Service Portfolio
Table 12.17 Cytovance Biologics: Recent Developments and Future
Table 12.18 Forge Biologics: Company Snapshot
Table 12.19 Forge Biologics: Service Portfolio
Table 12.20 Forge Biologics: Recent Developments and Future Outlook
Table 12.21 GenScript ProBio (a Subsidiary of GenScript): Company Snapshot
Table 12.22 GenScript ProBio (a Subsidiary of GenScript): Service Portfolio
Table 12.23 GenScript ProBio (a Subsidiary of GenScript): Recent Development and Future Outlook
Table 12.24 Patheon pharma services (acquired by Thermo Fisher Scientific): Company Snapshot
Table 12.25 Patheon pharma services (acquired by Thermo Fisher Scientific): Service Portfolio
Table 12.26 Patheon pharma services (acquired by Thermo Fisher Scientific): Recent Developments and Future Outlook
Table 12.27 VGXI: Company Snapshot
Table 12.28 VGXI: Service Portfolio
Table 12.29 VGXI: Recent Developments and Future Outlook
Table 12.30 53Biologics: Service Portfolio
Table 12.31 Boehringer Ingelheim: Service
Table 12.32 Centre for Breakthrough
Table 12.33 JAFRAL Biosolutions: Service
Table 12.34 PackGene: Service Portfolio
Table 12.35 Acural Bio: Service Portfolio
Table 12.36 Hanmi BioPlant: Service
Table 12.37 BioCina: Service Portfolio
Table 12.38 NorthXBiologics: Service
Table 12.39 Xpress Biologics: Service
Table 12.40 Eurogentec: Service Portfolio
Table 12.41 ESCO Aster: Service Portfolio
Table 12.42 Southern RNA: Service Portfolio
Table 12.43 Richter-Helm: Service Portfolio
Table 12.44 Aurigene Pharmaceutical: Service Portfolio
Table 12.45 Wuxi AppTech: Service Portfolio
Table 22.1 Plasmid DNA Service Providers: Distribution by Year of Establishment
Table 22.2 Plasmid DNA Service Providers: Distribution by Company Size
Table 22.3 Plasmid DNA Service Providers: Distribution by Location of Headquarters
Table 22.4 Plasmid DNA Service Providers: Distribution by Type of Company
Table 22.5 Plasmid DNA Service Providers: Distribution by Type of Venture
Table 22.6 Plasmid DNA Service Providers: Distribution by Type of Service(s) Offered
Table 22.7 Plasmid DNA Manufacturers: Distribution by Location of Manufacturing Facility
Table 22.8 Plasmid DNA Service Providers: Distribution by Key Offerings
Table 22.9 Plasmid DNA Service Providers: Distribution by Grade of Plasmid DNA
Table 22.10 Plasmid DNA Service Providers: Distribution by Scale of Operation
Table 22.11 Plasmid DNA Service Providers: Distribution by Application Area(s)
Table 22.12 Key Insights: Distribution by Company Size and Location of Headquarters
Table 22.13 Key Insights: Distribution by Company Size and Type of Venture
Table 22.14 Key Insights: Distribution by Key Offerings and Location of Headquarters
Table 22.15 Key Insights: Distribution by Scale of Operation and Company Size
Table 22.16 Key Insights: Distribution by Grade of Plasmid DNA and Application Area(s)
Table 22.18 Partnerships and Collaborations: Cumulative Year-Wise Trend, 2015-2023
Table 22.19 Partnerships and Collaborations: Distribution by Type of Partnership
Table 22.20 Partnerships and Collaborations: Distribution by Year and Type of Partnership, 2015-2023
Table 22.21 Partnerships and Collaborations: Distribution by Type of Partner
Table 22.22 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
Table 22.23 Partnerships and Collaborations: Distribution by Grade of Plasmid DNA
Table 22.24 Partnerships and Collaborations: Distribution by Scale of Operation
Table 22.25 Partnerships and Collaborations: Local and International Agreements
Table 22.26 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Table 22.27 Most Active Players: Distribution by Number of Partnerships
Table 22.28 Acquisitions: Cumulative Year-Wise Trend, 2015-2023
Table 22.29 Acquisitions: Distribution by Type of Acquisition
Table 22.30 Acquisitions: Local and International Deals
Table 22.31 Acquisitions: Intercontinental and Intracontinental Deals
Table 22.32 Acquisitions: Ownership Change Matrix
Table 22.33 Acquisitions: Distribution by Company Size
Table 22.34 Acquisitions: Distribution by Key Value Drivers
Table 22.35 Acquisitions: Valuation by Acquisition Deal Multiples
Table 22.36 Most Active Players: Distribution by Number of Acquisitions
Table 22.37 Minimum, Average and Maximum Installed Plasmid DNA Manufacturing Capacity (Sample Dataset) (in Liters): Distribution by Company Size
Table 22.38 Global Installed Plasmid DNA Manufacturing Capacity (in Liters): Distribution by Company Size
Table 22.39 Global Installed Plasmid DNA Manufacturing Capacity (in Liters): Distribution by Scale of Operation
Table 22.40 Global Installed Plasmid DNA Manufacturing Capacity (in Liters): Distribution by Location of Manufacturing Facility
Table 22.41 Company Competitiveness Analysis: Benchmarking of Service Strength
Table 22.42 Company Competitiveness Analysis: Benchmarking of Partnership Activity
Table 22.43 Danaher: Annual Revenues, 2017-2022 (USD Billion)
Table 22.44 Catalent Pharma Solutions: Annual Revenues, 2017-2022 (USD Billion)
Table 22.45 Charles River: Annual Revenues, 2017-2022 (USD Billion)
Table 22.46 GenScript: Annual Revenues, 2017-2022 (USD Billion)
Table 22.47 Thermo Fisher Scientific: Annual Revenues, 2017-2022 (USD Billion)
Table 22.48 Global Demand for Plasmid DNA, Historical Trends (2018-2022) (In Kgs)
Table 22.49 Global Demand for Plasmid DNA, Forecasted Estimates (2023-2035) (In Kgs)
Table 22.50 Demand for Plasmid DNA: Distribution by Scale of Operation, Historical Trends (2018-2022) (In Kgs)
Table 22.51 Demand for Plasmid DNA: Distribution by Scale of Operation, ForecastedEstimates (2023-2035) (In Kgs)
Table 22.52 Demand for Plasmid DNA: Distribution by Application Area, Historical Trends (2018-2022) (In Kgs)
Table 22.53 Demand for Plasmid DNA: Distribution by Application Area, ForecastedEstimates (2023-2035) (In Kgs)
Table 22.54 Demand for Plasmid DNA: Distribution by Geography, Historical Trends (2018-2022) (In Kgs)
Table 22.55 Demand for Plasmid DNA: Distribution by Geography, Forecasted Estimates (2023-2035) (In Kgs)
Table 22.56 Global Plasmid DNA Manufacturing Market, Historical Trends (2018-2022) (USD Billion)
Table 22.57 Global Plasmid DNA Manufacturing Market, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 22.58 Plasmid DNA Manufacturing Market: Distribution by Scale of Operation, Historical Trends (2018-2022) (USD Billion)
Table 22.59 Plasmid DNA Manufacturing Market: Distribution by Scale of Operation, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 22.60 Plasmid DNA Manufacturing Market: Distribution by Application Area,Historical Trends (2018-2022) (USD Billion)
Table 22.61 Plasmid DNA Manufacturing Market: Distribution by Application Area, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios
Table 22.62 Plasmid DNA Manufacturing Market: Distribution by Therapeutic Area, Historical Trends (2018-2022) (USD Billion)
Table 22.63 Plasmid DNA Manufacturing Market: Distribution by Therapeutic Area, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
Table 22.64 Plasmid DNA Manufacturing Market: Distribution by Geography, Historical Trend (2018-2022) (USD Billion)
Table 22.65 Plasmid DNA Manufacturing Market: Distribution by Geography, Forecasted Estimates (2023-2035), Conservative, Base and Optimistic Scenarios (USD Billion)
The following companies / institutes / government bodies and organizations have been mentioned in this report:
Source 1: https://www.news-medical.net/life-sciences/A-New-Breed-of-Vaccine-Exploring-Doggybone-e284a2-DNA-Technology.aspx
Source 2: https://www.genengnews.com/news/catalent-opens-new-commercial-scale-plasmid-dna-manufacturing-facility/
PRICING DETAILS
Discounts available for multiple report purchases
sales@rootsanalysis.com
YOU MAY ALSO LIKE
SUBSCRIBE TO INDUSTRY UPDATES